



Akasaka Intercity, 1-11-44, Akasaka, Minato-ku, Tokyo 107-0052
Phone +81-3-6299-8905 Fax +81-3-6299-8922
<http://corporate.m3.com> pr@m3.com

Acquisition of U.S. Clinical Trial Execution Facility
~ Three Additional Sites in California, Increased Access to 50 Thousand New Patients ~

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: <https://corporate.m3.com/en/>, "M3" below) announced the acquisition of businesses of Pharmacology Research Institute ("PRI," below), which operations clinical trial execution sites across California, through its U.S. entity, M3 USA Corporation.

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 250+ thousand physician members in Japan, offering marketing and clinical trial services. Presence outside of Japan include the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 4.5 million physicians as members across our global platforms, allows provision of services such as marketing support, marketing research, and job placement support that leverages on the platform's powerful value as a media channel.

The U.S. clinical trial business was launched in February 2018 through the acquisition of Wake Research Holdings LLC, which operated 12 organizational clinical trial facilities across the southern parts of the U.S.

PRI operations three clinical trial facilities around Los Angeles, and is highly esteemed within the neuroscience specialty area where new drugs are actively being developed, and can provide access to 50,000 patients in nearby areas. M3 will continue acquisition of clinical trial facilities in effort to create a clinical trial facility network that covers the U.S. nationwide.

M3 Group's Clinical Trial Facilities

